Bio-Path Holdings, Inc. (BPTH) Social Stream
Bio-Path Holdings Inc (BPTH) Price Targets From Analysts
Use the tables below to see what analysts covering Bio-Path Holdings Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
BPTH's average price target has moved up $2.5 over the prior 14 months.
Over the past 48 weeks, BPTH's average upside potential has been 124.58%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
BPTH Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 120 days, BPTH's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BPTH as an investment opportunity.
- Bio-Path Holdings Inc's number of analysts covering the stock is higher than 4.71% of all US stocks.
- BPTH has a lower variance in analysts' estimates than 85.32% of Pharmaceutical Products stocks.
- BPTH has a higher average analyst price target than 41.9% of Healthcare stocks.
- BPTH has a greater upside potential (average analyst target price relative to current price) than 145.72% of stocks in the small market cap category.
In the Pharmaceutical Products industry, BOLT, BLU, and BLCM are the three stocks most similar to Bio-Path Holdings Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for BPTH? Use POWR Ratings for clearer insight into price direction.